ClinicalTrials.gg
Active, not recruitingNCT03887455Clarity ADUpdated Oct 6, 2026

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

A Phase 3 interventional study of Lecanemab IV and Placebo in Early Alzheimer's Disease, sponsored by Eisai Inc.. Active, not recruiting at 247 sites in 14 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Updated Oct 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,906
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 46 studies in Alzheimer Disease by Eisai Co., Ltd. — 7 open to participants now, 12 under way, 2 of them phase 3. Alzheimer Disease · Eisai Co., Ltd..

Enrollment
2nd of 30
1,906 · median 99
Started
2019
the only one that year
Phase 3
8 of 46
none open now
Primary completion
2026-12
later than 0 of 11 live
Registered
34th of 46
by date

Among the 46 studies in Alzheimer Disease by Eisai Co., Ltd., this one is the 2nd largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2019, is one of 8 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 34th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

7 of the 46 studies in Alzheimer Disease by Eisai Co., Ltd. are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Alzheimer Disease by Eisai Co., Ltd., or all of them as a file.
02

Study summary

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. Extension Phase Part B will continue dosing with lecanemab in countries where lecanemab may not be commercially available.

Read the detailed description

All administrations of study drug will be administered in the clinic or in the home; However, home administrations of intravenous (IV) study drug will be allowed per sponsor approval according to country and local guidelines during the COVID-19 pandemic and following its resolution, where permitted.

03

Conditions studied

  • Early Alzheimer's Disease

Keywords

  • BAN2401
  • Clinical Dementia Rating-Sum of Boxes
  • Mild cognitive impairment
  • Alzheimer's disease/prodromal Alzheimer's disease
  • Mild Alzheimer's disease dementia
  • Clarity AD
  • Lecanemab
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Core Study: Inclusion Criteria

Diagnosis: Mild Cognitive Impairment (MCI) due to Alzheimer's disease - intermediate likelihood:

  • Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria for MCI due to Alzheimer's disease - intermediate likelihood
  • Have a global Clinical Dementia Rating (CDR) score of 0.5 and CDR Memory Box score of 0.5 or greater at Screening and Baseline
  • Report a history of subjective memory decline with gradual onset and slow progression over the last 1 year before Screening; must be corroborated by an informant

Mild Alzheimer's disease dementia:

  • Meet the NIA-AA core clinical criteria for probable Alzheimer's disease dementia
  • Have a global CDR score of 0.5 to 1.0 and a CDR Memory Box score of 0.5 or greater at Screening and Baseline

Key Inclusion Criteria that must be met by all participants:

  • Objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale IV-Logical Memory (subscale) II (WMS-IV LMII)
  • Positive biomarker for brain amyloid pathology
  • Male or female participants aged greater than or equal to (>=) 50 and less than or equal to (\<=) 90 years, at the time of
  • (MMSE) score >=22 at Screening and Baseline and \<=30 at Screening and Baseline
  • (BMI) greater than (>)17 and less than (\<) 35 at Screening
  • If receiving an approved Alzheimer's disease treatment such as acetylcholinesterase inhibitor (AChEIs) or memantine or both for Alzheimer's disease, must be on a stable dose for at least 12 weeks prior to Baseline. Treatment-naive participants for Alzheimer's disease can be entered into the study. Unless otherwise stated, participants must have been on stable doses of all other (that is, non-Alzheimer's disease-related) permitted concomitant medications for at least 4 weeks prior to Baseline. Use of memantine will not be allowed for participants in Japan
  • Have an identified study partner (defined as a person able to support the participant for the duration of the study and who spends at least 8 hours per week with the participant)
  • Provide written informed consent. If a participant lacks capacity to consent in the investigator's opinion, the participant's assent should be obtained, if required in accordance with local laws, regulations and customs, plus the written informed consent of a legal representative should be obtained (capacity to consent and definition of legal representative should be determined in accordance with applicable local laws and regulations). In countries where local laws, regulations, and customs do not permit participants who lack capacity to consent to participate in this study (example, Germany and Spain), they will not be enrolled

Extension Phase: Inclusion Criteria:

  • Participants who have completed the Core Study (except de novo participants)
  • Must continue to have a study partner who is willing and able to provide follow-up information on the participant throughout the course of the Extension Phase
  • Provide written informed consent for the Extension Phase. If a participant lacks capacity to consent in the investigator's opinion, the participant's assent should be obtained, if required and in accordance with local laws, regulations and customs, plus the written informed consent of a legal representative should be obtained (capacity to consent and definition of legal representative should be determined in accordance with applicable local laws and regulations). In countries where local laws, regulations, and customs do not permit participants who lack capacity to consent to participate in this study (example, Germany and Spain), they will not be enrolled
  • Participants entering the SC (vial) substudy at Extension Phase Week 1, must be willing to participate, or continue participating in the amyloid positron emission tomography (PET) substudy. All participants must have an amyloid PET scan within 4 weeks before starting SC BAN2401
  • Participants enrolling into the SC autoinjector substudy must have had at least 6 months exposure to BAN2401 10 mg/kg IV biweekly or at least 12 months exposure of BAN2401 Dose 1 subcutaneously weekly.
  • Participants enrolling into the SC Dose 3 autoinjector substudy must have previously received BAN2401 by either IV administration and/or SC autoinjector administration and must have completed Visit 82 (Extension Week 79) at a minimum, regardless of previous route of administration

Extension Phase Part B: Inclusion Criteria:

  • Must have completed Week 207 in the Extension Phase

Exclusion Criteria

  • Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease
  • History of (TIA), stroke, or seizures within 12 months of Screening
  • Any psychiatric diagnosis or symptoms (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant
  • Geriatric Depression Scale (GDS) score >=8 at Screening
  • to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (example in skull and cardiac devices other than those approved as safe for use in MRI scanners)
  • Evidence of other lesions on brain MRI at Screening that could indicate a dementia diagnosis other than Alzheimer's disease
  • Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter [mm] or less at the greatest diameter); a single macrohemorrhage >10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter [cm] at their greatest diameter need not be exclusionary)
  • Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic , or plasmapheresis during the study
  • Participants with a bleeding disorder that is not under adequate control (including a count \<50,000 or [INR] >1.5 for participants who are not on anticoagulant treatment, example, warfarin). Participants who are on anticoagulant therapy should have their anticoagulant status optimized and be on a stable dose for 4 weeks before Screening. Participants who are on anticoagulant therapy are not permitted to participate in cerebrospinal fluid (CSF) assessments
  • Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments
  • Participation in a clinical study involving any therapeutic monoclonal antibody, protein derived from a monoclonal antibody, immunoglobulin therapy, or vaccine within 6 months before screening unless it can be documented that the participant was randomized to placebo
  • Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapies and any β-site amyloid precursor protein cleaving enzyme [BACE] inhibitor therapies) unless it can be documented that the participant only received placebo
  • Participants who have any known prior exposure to lecanemab
  • Participants who were dosed in a clinical study involving any new chemical entities for AD within 6 months prior to screening unless it can be documented that the participant was in a placebo treatment arm

Extension Phase: Exclusion Criteria

  • Participants who discontinued early from the Core Study
  • Participants who develop the following conditions from the time of Screening for the Core Study to the start of the Extension Phase
  • Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD
  • Any psychiatric diagnosis or symptoms, (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant
  • Contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (example, in skull and cardiac devices other than those approved as safe for use in MRI scanners)
  • Other significant pathological findings on brain MRI during the Core Study including but not limited to: cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors will be exclusionary if based on the opinion of the investigator, with consultation of medical monitor, these findings may interfere with the study procedures or safety
  • to BAN2401 or any of the , or to any monoclonal antibody treatment
  • Any immunological disease which is not adequately controlled, or which requires chronic treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study
  • Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or , which in the opinion of the investigator require further investigation or treatment or which may interfere with study procedures or safety
  • Malignant neoplasms (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participants) that are not stably and adequately controlled or which, based on the opinion of the investigator, may interfere with the participant's safety or participation in the study
  • Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments
  • Severe visual or hearing impairment that would prevent the participant from performing psychometric tests accurately

Extension Phase Part B: Exclusion Criteria

-In countries where lecanemab is authorized for use in APOE4 noncarriers and heterozygous carriers only, APOE4 homozygous carriers will not be eligible for participation in Extension Phase Part B. Any APOE4 homozygous carriers that are already participating in Extension Phase Part B in such countries will be discontinued from the study.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,906 participants (actual)

Study arms

  • Experimental
    Core Study: Lecanemab 10 milligram per kilogram (mg/kg) biweekly

    Drug: Lecanemab IV

  • Placebo comparator
    Core Study: Placebo

    Drug: Placebo

  • Experimental
    Extension Phase: Lecanemab 10 mg/kg biweekly

    Drug: Lecanemab IV

  • Experimental
    Extension Phase: Lecanemab Subcutaneous (SC) Injection Dose 1

    This will include approximately 40 de novo participants (those that did not participate in the core study) with EAD.

    Drug: Lecanemab SC

  • Experimental
    Extension Phase: Lecanemab SC Injection Dose 2

    Drug: Lecanemab SC

  • Experimental
    Extension Phase: Lecanemab SC Injection Dose 3

    Drug: Lecanemab SC

  • Experimental
    Extension Phase: Lecanemab SC Injection Dose 4

    Drug: Lecanemab SC

  • Experimental
    Extension Phase: Lecanemab 10 mg/kg IV Infusion Once Every 4 Weeks (Q4W)

    Drug: Lecanemab IV

  • Experimental
    Extension Phase B

    Participants will receive Lecanemab 10 mg/kg IV infusion Q2W, or Q4W, or Dose 3, or Dose 4, SC injection, weekly.

    Drug: Lecanemab IV · Drug: Lecanemab SC

Interventions

  • Administered as IV infusion.

    Also known as: BAN2401

  • DrugPlacebo

    Biweekly (once every 2 weeks) administered as IVinfusion.

  • Administered weekly as a SC injection.

    Also known as: BAN2401

06

What researchers measure

Primary outcomes

  1. Core Study: Change from Baseline in the CDR-SB at 18 Months

    Time frame: Baseline, 18 months

  2. Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)

    A TEAE is defined as an adverse event (AE) that emerges during treatment or within 30 days of the last dose of study drug, having been absent at pretreatment (Baseline) or reemerges during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsens in severity during treatment relative to the pretreatment state, when the adverse event was continuous. Number of participants with TEAEs (serious and non-serious adverse events) will be reported based on their regular measurement of vital signs, safety assessments of laboratory tests, antidrug antibody assessments, suicidality assessments, magnetic resonance imaging and electrocardiogram parameter values.

    Time frame: From first dose of study drug up to approximately 51 months (including 3 months follow up) for the extension phase

  3. Extension Phase: Change from Core Study Baseline in CDR-SB

    Time frame: Baseline up to Month 66

  4. Extension Phase Part B: Number of Participants Exposed to Lecanemab

    Time frame: From 48th month in extension phase part A to the end of extension phase part B (up to 24 months)

Secondary outcomes

  1. Core Study: Change From Baseline in Amyloid Positron Emission Tomography (PET) Using Centiloids at 18 Months

    Time frame: Baseline, 18 months

  2. Core Study: Change from Baseline in Alzheimer Disease Assessment Scale - Cognitive Subscale 14 (ADAS-cog14) at 18 Months

    Time frame: Baseline, 18 months

  3. Core Study: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at 18 Months

    Time frame: Baseline, 18 months

  4. Core Study: Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS MCI-ADL) at 18 Months

    Time frame: Baseline, 18 months

  5. Core Study: Number of Participants Reporting One or More TEAEs

    A TEAE is defined as an AE that emerges during treatment or within 30 days of the last dose of study drug, having been absent at pretreatment (Baseline) or reemerges during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsens in severity during treatment relative to the pretreatment state, when the adverse event was continuous. Number of participants with TEAEs (serious and non-serious adverse events) will be reported based on their regular measurement of vital signs, safety assessments of laboratory tests, suicidality assessments, magnetic resonance imaging and electrocardiogram parameter values.

    Time frame: From first dose of study drug up to approximately 21 months (including 3 months follow-up)

  6. Core Study: Area Under the Curve of Lecanemab in Serum

    Time frame: Up to 21 months

  7. Core Study: Average Concentration (Cav) of Lecanemab in Serum

    Time frame: Up to 21 months

  8. Extension Phase Part B: Number of Participants Reporting AEs

    Time frame: From 48th month in extension phase part A to the end of extension phase part B (up to 24 months)

07

Study locations

247 sites

Showing the first 100 of 247 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Boustani M, Klein EG, Zimmer JA, Wang H, Engle SE, Phipps A, Japha M, Schilling T, Hartry A; Alzheimer's Disease Neuroimaging Initiative. Further data to address the Alzheimer's coverage with evidence development questions. Alzheimers Dement. 2026 Aug;22(8):e71724. doi: 10.1002/alz.71724. PubMed 42552749 ↗
  • Perry R, Kipps C, Soto Martin ME, Bozzali M, Logroscino G, Trafford S, Dhadda S, Kanekiyo M, Goodwin A, Hodgkinson M, Hersch S, Irizarry M, Kramer L, Froelich L. Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E epsilon4 (ApoE epsilon4) non-carriers or heterozygotes. J Prev Alzheimers Dis. 2026 Apr;13(4):100507. doi: 10.1016/j.tjpad.2026.100507. Epub 2026 Feb 13. PubMed 41689888 ↗
  • Devanarayan V, Horie K, Wildsmith K, Doherty T, Andreozzi E, Charil A, Sachdev P, Kramer LD, Dhadda S, Irizarry MC. Combining CSF MTBR-tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease. Alzheimers Dement. 2025 Nov;21(11):e70881. doi: 10.1002/alz.70881. PubMed 41170658 ↗
  • Devanarayan V, Ye Y, Zhu L, Tian L, Kramer L, Irizarry M, Dhadda S. Predicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency. Alzheimers Dement. 2025 Mar;21(3):e70045. doi: 10.1002/alz.70045. PubMed 40042496 ↗
  • Devanarayan V, Charil A, Horie K, Doherty T, Llano DA, Andreozzi E, Sachdev P, Ye Y, Murali LK, Zhou J, Reyderman L, Hampel H, Kramer LD, Dhadda S, Irizarry MC; Alzheimer's Disease Neuroimaging Initiative (ADNI). Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease. Alzheimers Dement. 2025 Feb;21(2):e14411. doi: 10.1002/alz.14411. Epub 2024 Nov 22. PubMed 39575854 ↗
  • Devanarayan V, Doherty T, Charil A, Sachdev P, Ye Y, Murali LK, Llano DA, Zhou J, Reyderman L, Hampel H, Kramer LD, Dhadda S, Irizarry MC. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimers Dement. 2024 Aug;20(8):5617-5628. doi: 10.1002/alz.14073. Epub 2024 Jun 28. PubMed 38940656 ↗
  • Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, Purcell D, Dhadda S, Irizarry M, Kramer L. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. Alzheimers Res Ther. 2024 May 10;16(1):105. doi: 10.1186/s13195-024-01441-8. PubMed 38730496 ↗
  • Tahami Monfared AA, Ye W, Sardesai A, Folse H, Chavan A, Aruffo E, Zhang Q. A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial. Neurol Ther. 2023 Jun;12(3):863-881. doi: 10.1007/s40120-023-00473-w. Epub 2023 Apr 2. PubMed 37009976 ↗
  • van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. PubMed 36449413 ↗

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Dec 2026, 93 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 93 months is above that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Jun 2029 → Dec 2026 and completion Jun 2029 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2019
First posted
Mar 25, 2019
StartActual
Mar 27, 2019
Primary completionEst.
Dec 31, 2026was Jun 2029
CompletionEst.
Dec 31, 2026was Jun 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
60 sites added, 60 sites removed
Show 60 added (33 Japan, 14 United States, 6 Germany, 2 France, 2 Italy, 2 Sweden, 1 Canada)
  • Sharp Neurocognitive Research Center · San Diego, United States
  • Advance Medical Research Center · Miami, United States
  • Advanced Clinical Research Network · Miami, United States
  • IMIC, Inc. · Miami, United States
  • Synexus Clinical Research US, Inc. · Orlando, United States
  • Charter Research · The Villages, United States
  • Synexus Clinical Research · The Villages, United States
  • Alzheimer's Research and Treatment Center · Wellington, United States
  • University of Kentucky Medical Center · Lexington, United States
  • McLean Hospital · Belmont, United States
  • ANI Neurology, PLLC d/b/a Alzheimer's Memory Center · Matthews, United States
  • NeuroScience Research Center LLC · Canton, United States
  • Keystone Clinical Studies, LLC · Plymouth Meeting, United States
  • Ralph H. Johnson VA Health Care System · North Charleston, United States
  • Centricity Research Halifax · Halifax, Canada
  • Centre de Neurologie Cognitive du Pr Paquet · Paris, France
  • Hôpitaux Universitaire de Strasbourg · Strasbourg, France
  • Bezirkskrankenhaus Guenzburg · Guenzburg, Germany
  • Central Institute o Mental Health - Department of Psychaitry · Mannheim, Germany
  • Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité Universitätsmedizin Berlin, Gedächtnissprechstunde am ECRC · Berlin, Germany
  • Neurozentrum Bielefeld Schwerpunktpraxis fuer Neurologie, Psychiatrie und Klinische · Bielefeld, Germany
  • Neuro Centrum Science GmbH · Erbach im Odenwald, Germany
  • TU Munchen · München, Germany
  • Ospedale "Card. G. Panico" - · Tricase, Italy
  • IRCCS San Gerado dei Tintori · Monza, Italy
  • National Center for Geriatrics and Gerontology · Obu-shi, Japan
  • Kashiwado hospital · Chiba, Japan
  • University of Fukui Hospital · Eiheiji-cho, Yoshida-gun, Japan
  • Shinozuka Hospital · Fujioka-shi, Japan
  • National Hospital Organizaton Hiroshima-Nishi Medical Center · Ōtake, Japan
  • …and 30 more on the registry record
Show 60 removed
  • Sharp Mesa Vista Hospital · San Diego, United States
  • North Bay Neuroscience Research Institute · Sebastopol, United States
  • Advanced Clinical Research Network · Coral Gables, United States
  • Charter Research · Lady Lake, United States
  • Alzheimer's Research and Treatment Center · Lake Worth, United States
  • Rios Medical Center, Inc. · Miami, United States
  • Bioclinica Research · Orlando, United States
  • IMIC, Inc. · Palmetto Bay, United States
  • Bioclinica Research · The Villages, United States
  • Partners Population Health · Belmont, United States
  • ANI Neurology, PLLC d/b/a Alzheimer's Memory Center · Charlotte, United States
  • OH Clinical Research Partners · Canton, United States
  • Keystone Clinical Studies, LLC · Norristown, United States
  • Roper St. Francis Healthcare · North Charleston, United States
  • True North Clinical Research Halifax, Inc. · Halifax, Canada
  • Hôpital de Hautepierre · Strasbourg, France
  • Hôpital Lariboisière · Paris, France
  • Eisai Trial Site #5 · Günzburg, Germany
  • Eisai Trial Site #2 · Mannheim, Germany
  • Eisai Trial Site #6 · Berlin, Germany
  • Eisai Trial Site #1 · Bielefeld, Germany
  • Eisai Trial Site #4 · Erbach im Odenwald, Germany
  • Eisai Trial Site #3 · München, Germany
  • Ospedale "Card. G. Panico" - · Tricase, Italy
  • ASST-Monza, Ospedale San Gerardo · Monza, Italy
  • Eisai Trial Site #4 · Obu-shi, Japan
  • Eisai Trial Site #15 · Chiba, Japan
  • Eisai Trial Site #6 · Yoshida-gun, Japan
  • Eisai Trial Site #1 · Fujioka-shi, Japan
  • Eisai Trial Site #32 · Ōtake, Japan
  • …and 30 more on the registry record
Oct 6, 2026
Primary completion
Jun 30, 2029→Dec 31, 2026
Oct 6, 2026
Study completion
Jun 30, 2029→Dec 31, 2026
Oct 6, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42552749 ↗
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42552749 ↗
    60 sites added, 60 sites removed
    Show 60 added (33 Japan, 14 United States, 6 Germany, 2 France, 2 Italy, 2 Sweden, 1 Canada)
    • Sharp Neurocognitive Research Center · San Diego, United States
    • Advance Medical Research Center · Miami, United States
    • Advanced Clinical Research Network · Miami, United States
    • IMIC, Inc. · Miami, United States
    • Synexus Clinical Research US, Inc. · Orlando, United States
    • Charter Research · The Villages, United States
    • Synexus Clinical Research · The Villages, United States
    • Alzheimer's Research and Treatment Center · Wellington, United States
    • University of Kentucky Medical Center · Lexington, United States
    • McLean Hospital · Belmont, United States
    • ANI Neurology, PLLC d/b/a Alzheimer's Memory Center · Matthews, United States
    • NeuroScience Research Center LLC · Canton, United States
    • Keystone Clinical Studies, LLC · Plymouth Meeting, United States
    • Ralph H. Johnson VA Health Care System · North Charleston, United States
    • Centricity Research Halifax · Halifax, Canada
    • Centre de Neurologie Cognitive du Pr Paquet · Paris, France
    • Hôpitaux Universitaire de Strasbourg · Strasbourg, France
    • Bezirkskrankenhaus Guenzburg · Guenzburg, Germany
    • Central Institute o Mental Health - Department of Psychaitry · Mannheim, Germany
    • Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité Universitätsmedizin Berlin, Gedächtnissprechstunde am ECRC · Berlin, Germany
    • Neurozentrum Bielefeld Schwerpunktpraxis fuer Neurologie, Psychiatrie und Klinische · Bielefeld, Germany
    • Neuro Centrum Science GmbH · Erbach im Odenwald, Germany
    • TU Munchen · München, Germany
    • Ospedale "Card. G. Panico" - · Tricase, Italy
    • IRCCS San Gerado dei Tintori · Monza, Italy
    • National Center for Geriatrics and Gerontology · Obu-shi, Japan
    • Kashiwado hospital · Chiba, Japan
    • University of Fukui Hospital · Eiheiji-cho, Yoshida-gun, Japan
    • Shinozuka Hospital · Fujioka-shi, Japan
    • National Hospital Organizaton Hiroshima-Nishi Medical Center · Ōtake, Japan
    • …and 30 more on the registry record
    Show 60 removed
    • Sharp Mesa Vista Hospital · San Diego, United States
    • North Bay Neuroscience Research Institute · Sebastopol, United States
    • Advanced Clinical Research Network · Coral Gables, United States
    • Charter Research · Lady Lake, United States
    • Alzheimer's Research and Treatment Center · Lake Worth, United States
    • Rios Medical Center, Inc. · Miami, United States
    • Bioclinica Research · Orlando, United States
    • IMIC, Inc. · Palmetto Bay, United States
    • Bioclinica Research · The Villages, United States
    • Partners Population Health · Belmont, United States
    • ANI Neurology, PLLC d/b/a Alzheimer's Memory Center · Charlotte, United States
    • OH Clinical Research Partners · Canton, United States
    • Keystone Clinical Studies, LLC · Norristown, United States
    • Roper St. Francis Healthcare · North Charleston, United States
    • True North Clinical Research Halifax, Inc. · Halifax, Canada
    • Hôpital de Hautepierre · Strasbourg, France
    • Hôpital Lariboisière · Paris, France
    • Eisai Trial Site #5 · Günzburg, Germany
    • Eisai Trial Site #2 · Mannheim, Germany
    • Eisai Trial Site #6 · Berlin, Germany
    • Eisai Trial Site #1 · Bielefeld, Germany
    • Eisai Trial Site #4 · Erbach im Odenwald, Germany
    • Eisai Trial Site #3 · München, Germany
    • Ospedale "Card. G. Panico" - · Tricase, Italy
    • ASST-Monza, Ospedale San Gerardo · Monza, Italy
    • Eisai Trial Site #4 · Obu-shi, Japan
    • Eisai Trial Site #15 · Chiba, Japan
    • Eisai Trial Site #6 · Yoshida-gun, Japan
    • Eisai Trial Site #1 · Fujioka-shi, Japan
    • Eisai Trial Site #32 · Ōtake, Japan
    • …and 30 more on the registry record
    Primary completion Jun 30, 2029→Dec 31, 2026
    Study completion Jun 30, 2029→Dec 31, 2026
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03887455
Lead sponsor
Eisai Inc.
Collaborators
Biogen
Responsible party
Sponsor
First posted
Mar 25, 2019
Start date
Mar 27, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lecanemab

Start the discussion